ARQT Q4 2023 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+356.8% YoY

Gross Profit

$11M83.4% margin

Operating Income

-$61M-452.2% margin

Net Income

-$66M-490.0% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

-64.5%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$56M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$341M

Total Liabilities

$253M

Stockholders' Equity

$89M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$3M	+356.8%
Gross Profit	$11M	$2M	+355.6%
Operating Income	-$61M	-$68M	+10.6%
Net Income	-$66M	-$72M	+8.0%

Revenue Segments

Product

$21M98%

Other Revenue

$420,0002%